Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454660 · ClinicalTrials.gov registry record · NA
Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages
A NA study of Medication Non Adherence, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 2
- Study locations
NCT02454660 is a NA study of Medication Non Adherence that has completed, run by University of Michigan. The registered enrollment target is 49 participants, below the 89-participant average among 3 other Medication Non Adherence trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02454660, a NA study of Medication Non Adherence, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 2
- Study locations
Study Summary
Uncontrolled hypertension is a major cause of morbidity and mortality and many patients fail to take their antihypertensive medication as prescribed. The investigators propose to use artificial intelligence (AI) to allow short message service (SMS or text messages) interventions to adapt to patients' adherence needs and substantially improve medication taking. The aims of the study are to: (1) develop AI methods for adaptive decision-making in human-centered environments and demonstrate the feasibility of the resulting AI-enhanced SMS medication adherence intervention, (2) demonstrate that the intervention can "learn" by adapting the SMS message stream according to patients' medication taking over time, and (3) examine potential intervention impact as measured by improvements in medication adherence and systolic blood pressures. The investigators will recruit 100 patients with uncontrolled hypertension and antihypertensive medication non-adherence. Adherence and other covariates will be measured via surveys at baseline, 3- and 6 months; blood pressures will be measured at baseline and 6 months. Participants will be given an electronic pill-bottle adherence monitor. Participants will receive SMS messages designed to motivate antihypertensive medication adherence. Message content and frequency will adapt automatically using AI algorithms designed to automatically optimize expected pill bottle opening. For Aim 1, the first 25 patients will be enrolled to develop and test alternative RL algorithms and fine-tune the system parameters. For Aim 2, the investigators will examine changes in the probability distribution over message-types and compare that distribution with patients' reasons for non-adherence reported at baseline. For Aim 3, the investigators will examine changes in self-reported medication non-adherence and blood pressure and automatically-reported pill bottle openings. This pilot study will establish the feasibility and potential impact of this novel approac
Conditions Studied
Interventions
- BEHAVIORAL SMS (Text messages)
Study Locations (2)
Michigan
- University of Michigan College of Pharmacy - Ann Arbor
- Spectrum Health - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02454660
The ClinicalTrials.gov registry entry for NCT02454660 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 3 other Medication Non Adherence trials with a reported enrollment target (45% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Medication Non Adherence appearing as the primary indexed condition, and to 1 intervention - of which SMS (Text messages) is the first listed.
NCT02454660 reports 2 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02454660 about?
NCT02454660 is a clinical study titled "Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages". Uncontrolled hypertension is a major cause of morbidity and mortality and many patients fail to take their antihypertensive medication as prescribed. The investigators propose to use artificial intelligence (AI) to allow short message service (SMS or text messages) interventions to adapt to patients...
What is the current status of trial NCT02454660?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2015-05. Estimated completion is 2016-11-04.
What conditions does trial NCT02454660 study?
This clinical trial studies the following conditions: Medication Non Adherence.
What interventions are being tested in trial NCT02454660?
The interventions under investigation include: SMS (Text messages) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02454660?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02454660 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medication Non Adherence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tailored Medication Management Intervention
COMPLETED · NA
-
A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness
COMPLETED · NA
-
Patient Centered Health Technology Medication Adherence Program for African American Hypertensives
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.